On June 7, 2021, the US Food and Drug Administration (FDA) approved aducanumab, 
a monoclonal amyloid targeting β-amyloid, for the treatment for Alzheimer's 
disease (AD). This decision was achieved through the Accelerated Approval 
Pathway and was essentially motivated by the evidence that aducanumab reduces 
brain amyloid plaques. This news is causing a heated debate in the scientific 
community. On the one hand, aducanumab is the first drug to be approved for the 
treatment of the disease since 2003 and is the first drug to act on the alleged 
pathophysiological mechanisms of AD. At the same time, the evidence of clinical 
benefit coming from two phase 3 clinical trials is contradictory and still 
inconclusive. The aim of the present editorial is to provide some points to 
consider that can help understand the peculiarities and implications of this 
approval and feed the scientific debate underway.